CLINICAL TRIAL article

Front. Psychiatry

Sec. Addictive Disorders

Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1545915

DMT and Harmala Alkaloids: An exploratory study of oral Acacia based formulations in Healthy Volunteers

Provisionally accepted
Amanda  NormanAmanda Norman1Amanda  NormanAmanda Norman1,2*
  • 1St Vincent's Hospital (Melbourne), Melbourne, Australia
  • 2The University of Melbourne, Parkville, Victoria, Australia

The final, formatted version of the article will be published soon.

Ayahuasca is a psychedelic compound of N, N, Dimethyltryptamine (DMT) and harmala alkaloids used for spiritual and medicinal applications in traditional settings. A range of potential psychotherapeutic mechanisms have been proposed for ayahuasca. These are thought to contribute to improvements in various psychiatric conditions including mood disorders and substance dependence. This open label exploratory study explored safety, tolerability, physical, mental health and psychedelic effects of three Acacia based formulations in 9 healthy volunteers with prior use of Ayahuasca. Formulations derived from two Acacia species (1mg/kg DMT and 4mg/kg of harmalas) were tested in a cross-over design in 5 adults; a third formulation (ACL-010) was tested in 4 adults at two dosages (1mg/kg DMT and 4mg/kg of harmalas, and then 1.4mg/kg DMT and 5.6mg of harmalas). All formulations had a good safety profile. No serious adverse events were reported. Physical examination, vital signs, and pathology revealed no clinically significant changes across the course of the study. The subjective experience of all formulations was generally rated similar to Ayahuasca. Four-week follow-up measures of psychological wellbeing and perceptual effects showed little difference between formulations. The strength and quality of the psychedelic experience elicited with ACL-010 was rated as similar or more beneficial than Ayahuasca. Our results indicate DMT formulations derived from the Acacia species represent a feasible alternative to traditional Ayahuasca for future clinical trials and possibly clinical contexts.The small sample size and open label design limit generalisabilitygeneralizability of results.

Keywords: ayahuasca, psychedelics, Plant medicine, Mental Health, Depression, Anxiety, Ethnobotany

Received: 16 Dec 2024; Accepted: 09 Jun 2025.

Copyright: © 2025 Norman and Norman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Amanda Norman, St Vincent's Hospital (Melbourne), Melbourne, Australia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.